- Abbott (ABT) completed U.S. enrollment for the TECTONIC IVL trial, presented late-breaking PFA/CSP data, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA.
- Abbott Laboratories closed Exact Sciences deal on March 23, 2026. Exact’s sales now sit in Abbott’s Cancer Diagnostics segment and are included in the segment’s comparable‑sales reporting.
- Abbott (ABT) kept full-year sales growth at 6.5–7.5% and raised adjusted EPS guidance, citing stronger diagnostics and diabetes care performance that boosted outlook.
- Abbott (ABT) Q2 2026 nutrition sales fell 3.1% YoY (comp sales -3.6%). US pediatric sales down 10.7%, international pediatric up 7.3%. Nutrition sales rose $127M sequentially.
TradingView
Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:ABT
- Language
- English
Abbott (ABT) completed U.S. enrollment for the TECTONIC IVL trial, presented late-breaking PFA/CSP data, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA.Abbott La